United Therapeutics Corporation (NASDAQ:UTHR – Free Report) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of United Therapeutics in a report released on Thursday, February 26th. HC Wainwright analyst A. Fein forecasts that the biotechnology company will post earnings of $6.93 per share for the quarter. HC Wainwright has a “Buy” rating and a $600.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q2 2026 earnings at $6.84 EPS, FY2027 earnings at $36.46 EPS and FY2030 earnings at $51.17 EPS.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business earned $6.19 EPS.
Read Our Latest Stock Report on United Therapeutics
United Therapeutics Trading Up 2.0%
Shares of NASDAQ UTHR opened at $513.82 on Monday. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $537.19. The stock’s fifty day simple moving average is $484.38 and its two-hundred day simple moving average is $449.32. The stock has a market capitalization of $22.52 billion, a PE ratio of 18.42, a price-to-earnings-growth ratio of 1.78 and a beta of 0.84.
Hedge Funds Weigh In On United Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of United Therapeutics by 1.6% in the second quarter. Envestnet Asset Management Inc. now owns 73,072 shares of the biotechnology company’s stock valued at $20,995,000 after purchasing an additional 1,163 shares during the period. Teacher Retirement System of Texas increased its stake in shares of United Therapeutics by 2.9% during the second quarter. Teacher Retirement System of Texas now owns 11,941 shares of the biotechnology company’s stock worth $3,431,000 after purchasing an additional 339 shares in the last quarter. Hantz Financial Services Inc. increased its stake in shares of United Therapeutics by 1,950.0% during the second quarter. Hantz Financial Services Inc. now owns 246 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 234 shares in the last quarter. Finally, Atria Investments Inc raised its position in shares of United Therapeutics by 12.6% during the 2nd quarter. Atria Investments Inc now owns 945 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.
Insider Buying and Selling
In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $478.60, for a total value of $10,050,600.00. Following the completion of the transaction, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $3,896,761.20. This trade represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $478.58, for a total transaction of $10,768,050.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 360,454 shares of company stock worth $174,796,043 in the last 90 days. 10.30% of the stock is currently owned by company insiders.
Key United Therapeutics News
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Ralinepag pivotal Phase 3 (ADVANCE OUTCOMES) met its primary endpoint, showing a 55% reduction in risk of clinical worsening versus placebo (highly statistically significant); company said it plans an FDA filing in 2026 — this is the principal catalyst supporting upside. United Therapeutics Announces Ralinepag Achieved 55% Reduction
- Positive Sentiment: Media reports highlight the ralinepag success and the company’s stated FDA filing plans, helping lift sentiment and trading activity. United Therapeutics’ Trial Shows 55% Drop in Lung Disease Worsening
- Positive Sentiment: Separate late‑stage study for a United Therapeutics blood‑pressure/pulmonary drug met its main and secondary endpoints, broadening the company’s late‑stage pipeline wins and de‑risking future revenue opportunities. United Therapeutics’ blood pressure drug meets main, secondary goals in late-stage study
- Positive Sentiment: Analyst bullishness followed: H.C. Wainwright raised its price target to $600 (Buy), signaling higher upside expectations based on the readouts and pipeline. H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600
- Neutral Sentiment: Management presented at the TD Cowen Health Care conference (transcript available) — useful for detail/QA but didn’t change the headline clinical results; read for color on timelines and commercialization plans. United Therapeutics Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Neutral Sentiment: Analyst notes and estimates are being updated (e.g., Q1 estimate and alternate target updates reported), reflecting recalibration of near‑term numbers while investors focus on longer‑term value from new approvals. Q1 Earnings Estimate for UTHR Issued By HC Wainwright United Therapeutics Price Target Raised to $466
- Negative Sentiment: Despite an EPS beat in the prior quarter, revenue slightly missed consensus — a reminder that near‑term top‑line performance could temper enthusiasm until new drug approvals begin to contribute.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
- Five stocks we like better than United Therapeutics
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
